Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)

• Status: Not yet recruiting
• Trial end date: 2021-04-14
• Target enrollment: 0
• Participant gender: All

Summary

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay.

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Xiyanping injection has anti-inflammatory and immune regulation effects. This study is a Randomized, Parallel Controlled Clinical Study to treat patients with COVID-19 infection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Treatments: Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

1. Aged >=18 years;

2. Novel coronavirus pneumonia patients diagnosed by pathogenic testing;

3. The patient himself participated in the study voluntarily, agreed and signed the informed consent.

Exclusion Criteria:

1. Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;

2. Severe primary diseases that affect survival, including: uncontrolled malignant tumors, hematological diseases, and HIV that have not been metastasized in multiple places;

3. Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and allergic alveolitis caused by lung tumors;

4. Women who are breastfeeding or pregnant;

5. Those who are known to be allergic to the ingredients contained in the research medication, or patients with allergies;

6. Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months;

7. Patients who have participated in other drug clinical trials within 3 months before the screening test;

8. The investigator judges that he or she cannot complete or should not participate in the study (expected death within 48 hours, and the patient refuses active treatment)